Saturday 17 October 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 26.7%, free cash flow fell 82.5% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.88
0.69
−2.42%
Follow VERA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 11.30 | 12.29 | 5.20 | 14.20 | 18.53 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 37.11 | 29.20 | 20.23 | 51.61 | 56.05 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 8 | 17 | 46 | 51 | 112 | 249 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (12) | (53) | (33) | (89) | (96) | (152) | (300) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (12) | (53) | (33) | (89) | (96) | (152) | (300) | |||||
| Depreciation | — | — | — | 1 | 0 | 0 | (1) | (4) | (8) | (5) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (40.13) | (166.93) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) | |||||
| Cash flow | — | — | — | (34.84) | (108.78) | (1.76) | (2.54) | (2.16) | (2.43) | (3.75) | |||||
| Capex | — | — | — | (0.42) | (0.13) | (0.37) | 0.00 | 0.00 | (0.02) | (0.01) | |||||
| Free cash flow | — | — | — | (35.27) | (108.91) | (2.14) | (2.55) | (2.16) | (2.45) | (3.76) | |||||
| Book value | — | — | — | 12.01 | 156.96 | 5.18 | 2.89 | 2.38 | 10.43 | 9.41 | |||||
| Shares, m | — | — | — | 0 | 0 | 13 | 27 | 43 | 55 | 64 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (10) | (35) | (24) | (68) | (92) | (135) | (241) | ||||
| Capex | — | — | — | 0 | 0 | (5) | 0 | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | (10) | (35) | (29) | (68) | (92) | (136) | (242) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 52 | 75 | 100 | 150 | 626 | 675 | ||||
| Total debt | — | — | — | 0 | 0 | 5 | 25 | 50 | 51 | 75 | |||||
| Net debt | — | — | — | (3) | (54) | (75) | (90) | (111) | (590) | (640) | |||||
| Shareholders’ equity | — | — | — | 4 | 50 | 70 | 77 | 102 | 577 | 605 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (440.59) | (178.24) | (47.16) | (82.77) | (62.54) | (36.61) | (43.10) | ||||
| ROIC | — | — | — | (2,065.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 18.83 | 84.85 | 330.12 | (121.58) | (107.50) | (44.83) | (50.71) | |||||
Negative figures in brackets.
Charts ten years each
Vera Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IRON Disc Medicine, Inc. | $2.2B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FTRE Fortrea Holdings Inc. | $2.2B | — (loss-making) | — (loss-making) | −4.52% (below 0%: shrinking) | n/m | +53.15% (above 0%: growing) | 20.52% | 2.18% | Compare |
| NVAX Novavax, Inc. | $2.1B | — (loss-making) | — (loss-making) | −76.30% (below 0%: shrinking) | n/m | +42.95% (above 0%: growing) | 74.87% | (96.84%) | Compare |
| VCEL Vericel Corporation | $2.1B | 83.6× | 76.8× | +22.48% (above 0%: growing) | n/m | +17,503.70% (above 0%: growing) | 72.82% | 0.56% | Compare |
| PHVS Pharvaris N.V. | $2.1B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VERA Vera Therapeutics, Inc. | $2.1B | — (loss-making) | — | — | n/m | −82.47% (below 0%: shrinking) | 0.00% | 0.00% | |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $1.9B | — (loss-making) | — (loss-making) | +259.25% (above 0%: growing) | n/m | +24.97% (above 0%: growing) | 93.30% | (247.07%) | Compare |
| Median of peers | $2.1B | — | — | +8.98% | — | +21.60% | 49.39% | 0.00% |
Vera Therapeutics, Inc. (VERA) key facts
- Concern: Vera Therapeutics, Inc. reported a net loss of $299.6 million, or a loss of $4.66 per share, for fiscal 2025.
- Vera Therapeutics, Inc. (VERA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, VERA traded at $27.88, a market capitalization of $2.1 billion.
- Return on equity was −50.7% and debt-to-equity 0.18.